TABLE 4.
Results of multi-adjusted regression models of case-control studies on the association between the metabolic syndrome, its components and VTE
Metabolic syndrome and VTE | ||
---|---|---|
Risk factor | OR | 95% CI |
Metabolic syndrome | 1.91 | 1.57-2.33 |
Age | 1.00 | 0.99-1.01 |
Obesity* | 1.56 | 1.28-1.89 |
Male sex | 1.67 | 1.42-1.97 |
Components of the metabolic syndrome and VTE | ||
Abdominal obesity† | 1.66 | 1.36-2.02 |
HDL cholesterol <40/50 mg/dL° | 1.48 | 1.24-1.77 |
Blood pressure ≥130/85 mmHg° | 1.41 | 1.17-1.70 |
Fasting glucose ≥100 mg/dL° | 1.26 | 1.04-1.53 |
Triglycerides≥150 mg/dL° | 1.24 | 1.02-1.51 |
Age | 1.00 | 0.99-1.01 |
Obesity* | 1.22 | 0.99-1.52 |
Male sex | 1.64 | 1.38-1.94 |
Caucasian patients: BMI > 30 Kg/m2 Asian patients: BMI > 25 Kg/m2
Caucasian patients: waist circumference > 102 cm for men and > 88 cm for women; Asian patients: waist circumference > 90 cm for men and > 80 cm for women
Patients currently receiving drug therapy for hypertension, diabetes, or dyslipidemia (only statins) were defined as having those disorders.